Management of Constipation in Cancer Patients with Tumor Obstruction

Critical First Step: Rule Out Complete Obstruction

The American Society of Clinical Oncology recommends obtaining a plain abdominal X-ray immediately to assess for complete bowel obstruction and extent of fecal loading before initiating any oral laxative therapy, as oral laxatives are contraindicated in this setting and can worsen symptoms or cause perforation in patients with tumor-related bowel obstruction 1, 2, 3, 4
A digital rectal examination (DRE) should be performed to identify rectal impaction or tumor masses that may be causing or contributing to obstruction in cancer patients with suspected bowel obstruction 1, 5
Enemas are absolutely contraindicated in patients with suspected intestinal obstruction, paralytic ileus, recent colorectal surgery, neutropenia, or thrombocytopenia, as they can cause perforation or worsen symptoms 1, 2

For patients with partial obstruction or no obstruction (constipation only), the European Society for Medical Oncology recommends osmotic laxatives (polyethylene glycol 17g daily, lactulose) or stimulant laxatives (senna, bisacodyl 10-15 mg 2-3 times daily, sodium picosulfate) as preferred first-line options 1, 2, 6
The American Society of Clinical Oncology recommends avoiding magnesium and sulfate salts in patients with renal impairment due to risk of hypermagnesemia 1, 2
Bulk laxatives (psyllium, fiber) are contraindicated in non-ambulatory patients with low fluid intake or suspected obstruction due to increased risk of mechanical obstruction 1, 2

The American Pain Society recommends that all patients receiving opioid analgesics should be prescribed prophylactic laxatives unless contraindicated by pre-existing diarrhea 1, 2
Osmotic or stimulant laxatives are generally preferred over stool softeners alone for the management of opioid-induced constipation 1, 2, 6
For refractory opioid-induced constipation unresponsive to laxatives, the European Society for Medical Oncology recommends considering peripherally acting μ-opioid receptor antagonists (PAMORAs) such as methylnaltrexone 0.15 mg/kg subcutaneously every other day 1, 2, 6

The American Society of Clinical Oncology recommends ensuring privacy and comfort for normal defecation, using proper positioning with a small footstool to assist gravity and facilitate straining, and increasing fluid intake to at least 2 liters daily within patient limits to help manage constipation in cancer patients 1, 2, 3, 7
Abdominal massage may reduce gastrointestinal symptoms, particularly in patients with neurogenic problems 1
Lifestyle modifications alone have limited influence and should never be the sole focus of management for constipation in cancer patients 3, 7

The American Society of Clinical Oncology recommends never administering oral laxatives without first excluding complete bowel obstruction through imaging, as this can cause perforation or worsen symptoms 4
Enemas should not be used in neutropenic or thrombocytopenic patients, or those with recent pelvic radiotherapy, due to increased risk of perforation or bleeding 1, 2, 6
Bulk-forming laxatives should be avoided in patients with suspected obstruction or limited mobility with low fluid intake due to increased risk of mechanical obstruction 1, 2, 6